Arcutis Biotherapeutics, Inc. Stock Price, News & Analysis

On February 18, 2021, Arcutis Biotherapeutics (Nasdaq: ARQT) announced that Courtney Barton joins as Chief Compliance Officer and Chief of Staff. Barton brings over 17 years of experience in corporate and healthcare compliance, having previously served as Vice President at Cipla Therapeutics. Her role will enhance Arcutis' compliance and data privacy efforts, aligning with the company's goal to establish itself as a leading innovation-driven medical dermatology firm. This strategic appointment is expected to support Arcutis' growth and commitment to integrity in operations.

Arcutis Biotherapeutics (NASDAQ: ARQT) announced positive Phase 3 results for its topical roflumilast cream targeting plaque psoriasis, with a New Drug Application (NDA) submission expected in H2 2021. The company plans to advance three additional programs into pivotal Phase 3 trials in 2021. Financially, Arcutis holds over $470 million in cash, providing a runway into 2023. R&D expenses rose significantly due to the initiation of multiple clinical trials, with a net loss of $135.7 million for 2020. The company aims to address unmet medical needs affecting over 20 million patients, with potential revenue opportunities of $3 to $8 billion.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the completion of a public offering, raising approximately $221.4 million by selling a total of 6,325,000 shares of common stock at $35 per share. The offering included the exercise of an overallotment option for an additional 825,000 shares. The funds are intended to support the development of Arcutis' pipeline, which focuses on immuno-dermatology treatments. Major underwriters for the offering included Morgan Stanley, Cowen, and Guggenheim Securities.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced a successful public offering of 5,500,000 shares at $35.00 each, aiming to raise $192.5 million before expenses. This upsized offering includes a 30-day option for underwriters to purchase an additional 825,000 shares. The proceeds will support the development of key programs, including ARQ-151 for psoriasis, and general operational needs. The offering is expected to close on February 5, 2021. Morgan Stanley, Cowen, and Guggenheim Securities are managing the offering.

Arcutis Biotherapeutics (Nasdaq: ARQT) has announced a public offering of $150 million in common stock, with all shares being sold by the company. The offering is subject to market conditions and includes a 30-day option for underwriters to purchase an additional 15% of the shares. The offering will be made under an automatic shelf registration statement filed with the SEC. Morgan Stanley, Cowen, and Guggenheim Securities are leading the offering, while details are available on the SEC’s website.

Arcutis Biotherapeutics announced positive results from its pivotal Phase 3 studies (DERMIS-1 and DERMIS-2) for roflumilast cream, a treatment for plaque psoriasis. The cream showed statistically significant improvement over a vehicle with an IGA Success rate of 42.4% and 37.5% in the respective studies (P<0.0001). With a favorable safety profile, only 1.7% and 0.3% of subjects discontinued due to adverse events. The company anticipates submitting a New Drug Application (NDA) to the FDA in the second half of 2021. Roflumilast cream could be the leading non-steroidal treatment for the 8.6 million plaque psoriasis patients in the U.S.

Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the advancement of its topical roflumilast foam (ARQ-154) into Phase 3 development for treating seborrheic dermatitis, following a successful End-of-Phase 2 meeting with the FDA. This pivotal trial is expected to start in Q2 or Q3 2021. Roflumilast foam has shown statistically significant improvement in clinical trials and possesses a favorable safety profile. Affecting over 10 million patients in the U.S., seborrheic dermatitis presents a significant market opportunity for this treatment, which could become a new standard of care.

Arcutis Biotherapeutics (Nasdaq: ARQT) has initiated pivotal Phase 3 clinical trials for its topical roflumilast cream aimed at treating atopic dermatitis (AD), which affects around 19 million people in the U.S. The trials, dubbed INTEGUMENT-1 and INTEGUMENT-2, will involve approximately 1,300 participants. Roflumilast cream is designed to be a once-daily, nonsteroidal treatment, offering a potential breakthrough in safety and efficacy for AD patients, particularly children. Topline data is anticipated in the second half of 2022, with a third study planned for younger patients.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the appointment of Matthew Moore as Chief Business Officer. With over 20 years in the biopharmaceutical industry, Moore previously led business development at Allergan’s Medical Aesthetics unit, generating over $4 billion. His addition is expected to strengthen Arcutis’ strategy in dermatology, enhancing shareholder value. Arcutis focuses on unmet needs in immuno-dermatology and is advancing four drug candidates to improve treatment for conditions like plaque psoriasis and atopic dermatitis.